Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma
Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma
复制标题
DOI：
10.1007/s12032-019-1261-5
复制
发表时间：
2019-04-01
期刊：
影响因子：
3.4
通讯作者：
Tanabe, Kazunari
中科院分区：
文献类型：
--
作者：
Ishihara, Hiroki;Takagi, Toshio;Tanabe, Kazunari
在转移性肾细胞癌（mRCC）的免疫检查点抑制剂治疗中，最佳肿瘤缓解（bTR）的幅度与患者生存期之间的相关性尚不清楚。在这篇文章中，我们回顾性研究了nivolumab治疗mRCC中bTR大小的预后相关性。对至少一种分子靶向治疗失败后接受纳武利尤单抗治疗的55例患者进行了评估。基于实体瘤疗效评价标准（RECIST）v.1.1评估bTR的大小。终点是nivolumab治疗开始后的无进展生存期（PFS）和总生存期（OS）。关于bTR的程度，分别在3例（5.46%）、15例（27.3%）、19例（34.5%）和18例（32.7%）患者中观察到完全缓解、部分缓解、疾病稳定和疾病进展。PFS和OS与bTR的大小显著相关（中位PFS：未达到（N.R.）[95%置信区间（CI）16.8-N.R.]对比13.0 [8.38-56.0]对比5.95 [4.27-7.30]对比1.92 [0.53-3.91]个月，p
The correlation between the magnitudes of best tumor response (bTR) and patient survival in immune checkpoint inhibitor therapy for metastatic renal cell carcinoma (mRCC) remains unclear. In this article, we retrospectively investigated the prognostic association of the magnitude of bTR in nivolumab therapy for mRCC. Fifty-five patients treated with nivolumab after failure of at least one molecular-targeted therapy were evaluated. Assessment of the magnitude of bTR was based on the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Endpoints were progression-free survival (PFS) and overall survival (OS) after the initiation of nivolumab therapy. In regard to the magnitude of bTR, complete response, partial response, stable disease, and progressive disease were observed in three (5.46%), 15 (27.3%), 19 (34.5%), and 18 (32.7%) patients, respectively. PFS and OS were significantly correlated with the magnitude of bTR (median PFS: not reached (N.R.) [95% confidence interval (CI) 16.8-N.R.] vs. 13.0 [8.38-56.0] vs. 5.95 [4.27-7.30] vs. 1.92 [0.53-3.91] months, p